Cargando…
Safety and Immunogenicity of a DNA SARS-CoV-2 vaccine (ZyCoV-D): Results of an open-label, non-randomized phase I part of phase I/II clinical study by intradermal route in healthy subjects in India
BACKGROUND: ZyCoV-D is a DNA vaccine candidate, which comprises a plasmid DNA carrying spike-S gene of SARS-CoV-2 virus along with gene coding for signal peptide. The spike(S) region includes the receptor-binding domain (RBD), which binds to the human angiotensin converting Enzyme (ACE)-2 receptor a...
Autores principales: | Momin, Taufik, Kansagra, Kevinkumar, Patel, Hardik, Sharma, Sunil, Sharma, Bhumika, Patel, Jatin, Mittal, Ravindra, Sanmukhani, Jayesh, Maithal, Kapil, Dey, Ayan, Chandra, Harish, Rajanathan, Chozhavel TM, Pericherla, Hari PR, Kumar, Pawan, Narkhede, Anjali, Parmar, Deven |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8285262/ https://www.ncbi.nlm.nih.gov/pubmed/34308319 http://dx.doi.org/10.1016/j.eclinm.2021.101020 |
Ejemplares similares
-
Efficacy, safety, and immunogenicity of the DNA SARS-CoV-2 vaccine (ZyCoV-D): the interim efficacy results of a phase 3, randomised, double-blind, placebo-controlled study in India
por: Khobragade, Akash, et al.
Publicado: (2022) -
Immunogenic potential of DNA vaccine candidate, ZyCoV-D against SARS-CoV-2 in animal models
por: Dey, Ayan, et al.
Publicado: (2021) -
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Oral NLRP3 Inflammasome Inhibitor ZYIL1: First‐in‐Human Phase 1 Studies (Single Ascending Dose and Multiple Ascending Dose)
por: Parmar, Deven V., et al.
Publicado: (2022) -
Phase I Clinical Study of ZYAN1, A Novel Prolyl-Hydroxylase (PHD) Inhibitor to Evaluate the Safety, Tolerability, and Pharmacokinetics Following Oral Administration in Healthy Volunteers
por: Kansagra, Kevinkumar A., et al.
Publicado: (2017) -
Pharmacokinetics, Safety, and Tolerability of Saroglitazar (ZYH1), a Predominantly PPARα Agonist with Moderate PPARγ Agonist Activity in Healthy Human Subjects
por: Jani, Rajendra H., et al.
Publicado: (2013)